fetching data ...

AB0314 (2021)
SEMAPHORIN 3A LEVELS IN LUPUS WITH AND WITHOUT SECONDARY ANTIPHOSPHOLIPID ANTIBODY SYNDROME AND RENAL INVOLVEMENT
G. S. Kart-Bayram1, D. Bayram1, A. Erden2, S. C. Güven2, B. Özdemir2, H. Apaydin2, A. Omma2, Ö. Karakaş2, B. Armagan2, K. Gok2, Y. Maraş2, O. Ateş3, C. Topçuoğlu3, O. Küçükşahin2, S. Erten2
1Ankara Şehir Hastanesi, Internal Medicine, Ankara, Turkey
2Ankara Şehir Hastanesi, Rheumatology, Ankara, Turkey
3Ankara Şehir Hastanesi, Biochemical, Ankara, Turkey

Background: In this study, we aimed to evaluate sema3A levels in SLE patients with and without renal involvementor secondary antiphospholipid antibody syndrome (APS), to further elucidate the contribution ofsema3A in etiopathogenesis these conditions


Objectives: Aim of this study is to evaluate sema3A levels in systemic lupus erythematosus patients (SLE) with and without renal involvement and secondary antiphospholipid antibody syndrome (APS).


Methods: SLE patients were grouped according to presence of secondary APS or renal involvement. The control group consisted of age-matched, non-smoker, healthy volunteers. Sema3A levels were compared among groups. All SLE patients were regrouped according to presence of thrombotic events, miscarriages and proteinuria and sema3A levels were investigated. Finally, sema3A levels of all SLE patients as a single group were compared to controls.


Results: The mean sema3A values were 16.16±2.84 ng/dL in the control group, 11.28±5.23 ng/dL in SLE patients without nephritis and APS, 9.05±5.65 ng/dL in SLE with APS group, and 8.53±5.11 ng/dL in lupus nephritis group. When all three patient groups were examined as a single group, mean sema3A value was significantly lower than that of the control group. Sema3A was reduced in SLE patients with thromboembolism and/or miscarriage.


Conclusion: Sema3A levels were lower in all patient groups compared to the control group. Moreover, the reduced sema3A levels in patients with a history of thromboembolism and/or miscarriage suggests that sema3A may play an important role in the pathogenesis of vasculopathy


Comparison of sema3A levels between SLE patient groups and control subjects

Patient groups
Group A (N=20) Group B (N=20) Group C (N=19) Control (N=19) p
Sema3A, ng/dL, mean ± SD 9.05 ± 5.65 11.28 ± 5.23 8.53 ± 5.11 16.16 ± 2.84 Group A vscontrol<0.001
Group B vscontrol<0.001
Group C vscontrol<0.001
Group A vs B = 0.203
Group A vs C = 0.766
Group B vs C = 0.106
All patients (N=59) Control (N=19) <0.001
9.64 ± 5.38 16.16 ± 2.84
Patients with thrombotic events and/or miscarriages (N=31) Patients without thrombotic events and/or miscarriages (N=48) 0.032
9.96 ± 5.11 12.33 ± 5.84
Patients with proteinuria and/or thrombotic events and/or miscarriages (N=45) Patients without proteinuria and/or thrombotic events and/or miscarriages (N=34) <0.001
9.05 ± 5.09 14.91± 4.50

Disclosure of Interests: None declared

Citation: Ann Rheum Dis, volume 80, supplement 1, year 2021, page 1182
Session: SLE, Sjögren’s and APS - clinical aspects (other than treatment) (Publication Only)